<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460642</url>
  </required_header>
  <id_info>
    <org_study_id>IND 74,817</org_study_id>
    <nct_id>NCT00460642</nct_id>
  </id_info>
  <brief_title>GnRH Antagonist to Prepare Recipients for Embryo Transfer</brief_title>
  <official_title>Use of GnRH Antagonist (Cetrotide) Protocol, Instead of Agonist, to Prepare Recipients for Embryo Transfer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Human Reproduction (IHR)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Human Reproduction (IHR)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      26% of all ART cycles performed in the USA in 2003 (CDC data) are frozen embryo transfers&#xD;
      (FET) and transfer of embryos resulting from egg donation (ED) to recipients. The typical&#xD;
      protocol used to prepare a recipient for ET involves GnRH agonist (Lupron, Tap&#xD;
      Pharmaceuticals) to down regulate the patient. A GnRH antagonist, such as Cetrotide (EMD&#xD;
      Serono), is comparable to GnRH agonist and FDA approved to prevent spontaneous ovulation with&#xD;
      ART treatment, and its usage decreases significantly the number of injections that the&#xD;
      patient receives with treatment. The working hypothesis for this study is that the GnRH&#xD;
      antagonist (Cetrotide) can be used instead of an agonist to achieve effective down regulation&#xD;
      in FET and ED cycles. Presumably, patients will prefer Cetrotide over Lupron because of the&#xD;
      markedly fewer injections required.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Pregnancy Rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delivery Rate</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Infertility</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH Antagonist (Cetrotide)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of infertility before cryopreserving the embryos or inability to conceive from&#xD;
             her own oocytes (based on age and/or a serum FSH &gt; 15 IU/L).&#xD;
&#xD;
          -  Any patient desiring to become pregnant as a result of transferring frozen-thawed&#xD;
             embryos generated using her own or donor oocytes.&#xD;
&#xD;
          -  Subject is in good health as determined by the Investigator on the basis of medical&#xD;
             history, physical examination and laboratory screening tests.&#xD;
&#xD;
          -  A negative pregnancy test prior to starting treatment with estrogens.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with a history of liver and/or kidney disease&#xD;
&#xD;
          -  Hypertension: systolic pressure over 180 mm Hg or diastolic pressure over 105 at any&#xD;
             study visit, measured twice 6 hours apart despite active treatment for hypertension.&#xD;
&#xD;
          -  Liver function tests of two times than the upper limit of normal&#xD;
&#xD;
          -  Women with active sever endometriosis.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilan Tur-Kaspa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>President and Medical Director, Institute for Human Reproduction (IHR) and Director, Clinical IVF-PGD Program, Reproductive Genetics Institute (RGI).</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Human Reproduction (IHR)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Human Reproduction (IHR)</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.infertilityIHR.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>April 12, 2007</study_first_submitted>
  <study_first_submitted_qc>April 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2007</study_first_posted>
  <last_update_submitted>May 24, 2010</last_update_submitted>
  <last_update_submitted_qc>May 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2010</last_update_posted>
  <keyword>Frozen embryo transfers (FET).</keyword>
  <keyword>Egg donation (ED).</keyword>
  <keyword>IVF.</keyword>
  <keyword>ART.</keyword>
  <keyword>Implantation.</keyword>
  <keyword>GnRH antagonist.</keyword>
  <keyword>Cetrotide.</keyword>
  <keyword>Endometrial response.</keyword>
  <keyword>Infertility treatments:</keyword>
  <keyword>Transfer of embryos from egg donation (ED) to recipients.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetrorelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

